Literature DB >> 9156265

Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.

C Salat1, E Holler, H J Kolb, R Pihusch, B Reinhardt, E Hiller.   

Abstract

To investigate endothelial cell alterations in BMT recipients developing acute graft-versus-host disease (aGVHD) we determined levels of the endothelial cell markers von Willebrand factor (VWF) and thrombomodulin (TM) in 57 patients undergoing BMT. Before conditioning VWF and TM levels did not differ significantly between transplant recipients who later developed no or mild (grade I) aGVHD (group A, allogeneic n = 22, autologous n = 7; VWF 136.0 +/- 44.1%; TM 29.5 +/- 18.0 ng/ml), and those with moderate or severe (grade II or III) aGVHD (group B, n = 28; VWF 142.2 +/- 37.6%; TM 35.2 +/- 20.1 ng/ml). A first significant rise of both VWF and TM level was noted after conditioning (day 0) both in group A (VWF 197.0 +/- 113.3%; P < 0.001; TM 39.3 +/- 23.3 ng/ml; P < 0.01) as well as in group B (VWF 201.7 +/- 53.3%; P < 0.0001; TM 43.5 +/- 23.5 ng/ml; P < 0.05). Subgroup analysis of autografted patients revealed no significant increase after conditioning in these patients. At the time of engraftment and onset of aGVHD (day 21), when VWF and TM levels within the groups were significantly elevated as compared with baseline (day -8) levels, group B patients (62.7 +/- 38.5 ng/ml) had significantly higher (P < 0.01) TM levels than patients of group A (37.4 +/- 19.6 ng/ml). This significant elevation also persisted at the end of the investigational period (day 28; group B: 56.0 +/- 37.6 ng/ml; group A: 38.2 +/- 23.7 ng/ml; P < 0.01). An elevation of endothelial cell markers is found in the course of BMT, particularly after conditioning and at the time of engraftment. This increase is pronounced in patients with aGVHD suggesting not only epithelial cell but also endothelial cell injury during aGVHD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156265     DOI: 10.1038/sj.bmt.1700767

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

1.  Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation.

Authors:  Nick Beije; Jurjen Versluis; Jaco Kraan; Jan W Gratama; Stefan Sleijfer; Jan J Cornelissen
Journal:  Haematologica       Date:  2015-02-20       Impact factor: 9.941

2.  Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

Authors:  Ioannis Politikos; Haesook T Kim; Theodoros Karantanos; Julia Brown; Sean McDonough; Lequn Li; Corey Cutler; Joseph H Antin; Karen K Ballen; Jerome Ritz; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-21       Impact factor: 5.742

3.  Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Di-Min Nie; Qiu-Ling Wu; Xia-Xia Zhu; Ran Zhang; Peng Zheng; Jun Fang; Yong You; Zhao-Dong Zhong; Ling-Hui Xia; Mei Hong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

4.  Acquired storage-pool disorders occurring late after allogeneic bone marrow transplantation: partial activation of platelets in asymptomatic patients.

Authors:  C Sakashita; H Akiyama; Y Satoh; T Inoue; K Ohashi; S Mori; H Sakamaki; K Hiruma; M Endoh; N Akamatsu; K Tanoue
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

5.  CD57+ T cells augment IFN-gamma production in a one-way mixed lymphocyte reaction and their expansion after stem cell transplantation in paediatric patients.

Authors:  Y Koike; S Seki; T Ohkawa; T Kaneko; K Kogawa; S Fujitsuka; H Hiraide; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

6.  Endothelial damage is aggravated in acute GvHD and could predict its development.

Authors:  E Mir; M Palomo; M Rovira; A Pereira; G Escolar; O Penack; E Holler; E Carreras; M Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

Review 7.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Thrombotic microangiopathy in haematopoietic cell transplantation: an update.

Authors:  Evi Stavrou; Hillard M Lazarus
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-11-03       Impact factor: 2.576

9.  Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Authors:  Beata Przybyla; Anne Pinomäki; Jari Petäjä; Lotta Joutsi-Korhonen; Karin Strandberg; Andreas Hillarp; Ann-Kristin Öhlin; Tapani Ruutu; Liisa Volin; Riitta Lassila
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

Review 10.  Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.

Authors:  Thomas Luft; Peter Dreger; Aleksandar Radujkovic
Journal:  Bone Marrow Transplant       Date:  2021-07-12       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.